These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3894723)

  • 21. Connective tissue disease in India. III. Clinical and immunological profile of progressive systemic sclerosis.
    Malaviya AN; Adhar GC; Pasricha JS
    J Assoc Physicians India; 1979 May; 27(5):395-400. PubMed ID: 316815
    [No Abstract]   [Full Text] [Related]  

  • 22. [Significance of anti-centromere antibodies. Clinical value].
    Meyer O; Haim T; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):261-6. PubMed ID: 6348931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma).
    Rothfield NF; Rodnan GP
    Arthritis Rheum; 1968 Oct; 11(5):607-17. PubMed ID: 4176069
    [No Abstract]   [Full Text] [Related]  

  • 24. The spectrum of scleroderma.
    LeRoy EC; Lomeo R
    Hosp Pract (Off Ed); 1989 Oct; 24(10A):33-42 contd. PubMed ID: 2509491
    [No Abstract]   [Full Text] [Related]  

  • 25. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
    Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
    Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases.
    Poirier TJ; Rankin GB
    Am J Gastroenterol; 1972 Jul; 58(1):30-44. PubMed ID: 4537959
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical aspects of progressive systemic scleroderma (PSS). Multicenter studies of 194 patients].
    Goerz G; Hammer G; Wirth G; Hornstein OP; Keller GJ; Altmeyer P; Holzmann H; Meigel W; Mensing H; Braun-Falco O
    Hautarzt; 1986 Jun; 37(6):320-4. PubMed ID: 3522484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The Scl-70 antibody and its clinical significance].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1989; 175(3):133-47. PubMed ID: 2653887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum antinuclear antibodies (in patients with visceral erythematodes, rheumatoid arthritis, progressive systemic sclerosis and discoid erythematodes)].
    Horvat Z
    Acta Med Iugosl; 1970; 24(3):229-40. PubMed ID: 4928076
    [No Abstract]   [Full Text] [Related]  

  • 30. [Detection of antinuclear antibodies using chicken erythrocytes in lupus erythematosus, scleroderma, rheumatoid arthritis and juvenile chronic arthritis].
    Lucić N; Bosković B
    Med Arh; 1985; 39(2-3):65-8. PubMed ID: 3917218
    [No Abstract]   [Full Text] [Related]  

  • 31. Antinuclear antibodies as immunologic markers for a benign subset and different clinical characteristics of scleroderma.
    Kleinsmith DM; Heinzerling RH; Burnham TK
    Arch Dermatol; 1982 Nov; 118(11):882-5. PubMed ID: 6753766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Determination of anti-Scl-70 antibody and its clinical significance in progressive systemic sclerosis].
    Jiang M
    Zhonghua Yi Xue Za Zhi; 1986 Jun; 66(6):346-8, 384. PubMed ID: 3094898
    [No Abstract]   [Full Text] [Related]  

  • 33. Epidermal nucleolar IgG deposition in clinically normal skin: clinical and serologic features of eight patients.
    Prystowsky SD; Gilliam JN; Tuffanelli DL
    Arch Dermatol; 1978 Apr; 114(4):536-8. PubMed ID: 348111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Significance and diagnostic value of different types of antinuclear antibodies demonstrated by immunofluorescence on smears of trypanosomed mice blood].
    Monier JC; Thivolet J; Sepetjian M; Beyvin AJ; Pousset G
    Lyon Med; 1970 May; 223(20):1007-18. PubMed ID: 4913277
    [No Abstract]   [Full Text] [Related]  

  • 35. Antinucleolar antibodies. Their frequency and diagnostic association.
    Ritchie RF
    N Engl J Med; 1970 May; 282(21):1174-8. PubMed ID: 4909324
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical and laboratory characteristics of patients with speckled pattern antinuclear antibodies.
    McMillan SA; Fay AC; Taggart AJ; McCrea JD; Roberts SD; Boyd MW; Nelson JK; Haire M
    Ulster Med J; 1986 Oct; 55(2):112-7. PubMed ID: 3492803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-Scl-70 antibodies in systemic scleroderma].
    Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
    Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of three methods for the detection of anti-SCL70 autoantibodies].
    Yalaoui S; Gorgi Y; Ayed K
    Ann Biol Clin (Paris); 2001; 59(5):639-42. PubMed ID: 11602398
    [No Abstract]   [Full Text] [Related]  

  • 39. [Better characterization of antinuclear factors (proceedings)].
    Stojan B
    Z Rheumatol; 1976; 35 Suppl 4():suppl 427-32. PubMed ID: 790835
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antinuclear antibody profile of progressive systemic sclerosis].
    Dong Y; Chen PZ; Chen M
    Zhonghua Nei Ke Za Zhi; 1987 Mar; 26(3):155-7, 190. PubMed ID: 3497783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.